Navigation Links
Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients

KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data have demonstrated that relapsing-remitting multiple sclerosis (RRMS) patients treated with COPAXONE(R) (glatiramer acetate injection) following brief immunosuppression with mitoxantrone experienced a 90 percent reduction in magnetic resonance imaging (MRI)-monitored disease activity compared to their baseline. These benefits were achieved early on and were sustained throughout the 24-month study period. These long-term data were consistent with the 15-month initial results of this study, previously presented at an international meeting on multiple sclerosis (MS), which demonstrated that the induction treatment strategy was more effective than COPAXONE(R) alone on reducing relapses and MRI measures of disease activity (p=0.0147). Treatment with COPAXONE(R) after induction with mitoxantrone remained safe and effective throughout the treatment period.

These new findings were presented at the 59th Annual Meeting of the American Academy of Neurology (AAN) along with new confirming MRI findings from the 15-month study, which showed that the decreases in clinical and MRI markers of disease activity, were accompanied by favorable effects on disease burden and irreversible brain tissue damage as shown by significant decreases in the accumulation of lesion load, and significant reduction in the proportion of lesions evolving into chronic black holes.

"This combination therapy is emerging as a promising treatment option for patients who have active RRMS, or who are not responding optimally to traditional first-line therapies," said Tim Vollmer, M.D., Director, Neuroimmunology Program, Barrow Neurological Institute at St. Joseph's Hospital and Medical Center and the primary investigator in this study. "This study builds on earlier studies that demonstrate the effect of COPAXONE(R) on disease activity and inflammation in the central nervous system of RRMS pati
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
2. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
3. Data on Higher Dose of Copaxone and Data Showing Copaxone is Most Cost Effective
4. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
5. First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
6. Point of Care Strep Tests Speed Treatment, Lower Costs
7. Rapid HIV Testing Increases Possibility of Treatment
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:10/31/2014)... , October 31, 2014 Investor-Edge ... (NASDAQ: NSPH ), Isis Pharmaceuticals Inc. (NASDAQ: ... HALO ), ACADIA Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, ...
(Date:10/31/2014)... (OTCQB:ECIA), a medical device company owning patented surgical technology ... surgery, today announced financial results for its fiscal 2015 ... Company posted quarterly net revenue of $2.279 million for ... per share. These results compare to net revenue of ... or $(0.01) per share, in the year-ago quarter. Gross ...
(Date:10/31/2014)... 2014 Research ... of the  "Process Validation in the US and ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key topics to ... Approach to Process Validation for Pharmaceutical and Biopharmaceutical ... FDA Process Validation Guidance EU Process ...
Breaking Medicine Technology:Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5Encision Reports Second Quarter Fiscal Year 2015 Results 2Encision Reports Second Quarter Fiscal Year 2015 Results 3Encision Reports Second Quarter Fiscal Year 2015 Results 4Encision Reports Second Quarter Fiscal Year 2015 Results 5Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4
... The U.S. Food and Drug Administration today issued draft ... previously cleared 510(k) device require a new premarket submission. ... The 510(k) process is the most common review path ... a device, manufacturers must submit a premarket notification or ...
...   UK pharma group ... quarter but highlights strong underlying sales momentum. ... CEO Andrew Witty and CFO Simon Dingemans review Q2 ... strategy, improving margins and a review of the recently ...
Cached Medicine Technology:FDA Issues Draft Guidance on Device Changes That Warrant New Premarket Review 2
(Date:10/31/2014)... The Memory Healer review published by DailyGossip.org ... whose father suffered from Alzheimer's disease. , In fact, ... his father's disease. His father pointed a gun and shot ... when the author of this method understood that he needed ... Memory Healer program is based on years of research. The ...
(Date:10/31/2014)... Lee's Summit, Missouri (PRWEB) October 31, 2014 ... circulated the country about families narrowly escaping carbon monoxide ... winter season) looms just weeks away, one family-owned, Missouri-based ... and straightforward approach to making sure families start the ... systems are safe and secure. , Beginning Nov. ...
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Surgery for low back ... in the United States you live, a new report ... low back pain at some point in their lives, ... medical care for a spine problem," co-author Brook Martin, ... Practice, said in a college news release. In ...
(Date:10/31/2014)... is a major contributor to deaths caused by motor ... underscore the importance of the "Sleep Well, Be Well" ... Results show that the risk of unintentional fatal injury ... insomnia symptoms present. People with all three symptoms of ... a fatal injury than those with no insomnia symptoms, ...
(Date:10/31/2014)... The Suspension Revolution review published by ... developed by Dan Long, a suspension training specialist. ... professional and life coach. The author of this program ... is not impossible , The Suspension Revolution review reveals ... training promises efficiency when it comes to burning fat, ...
Breaking Medicine News(10 mins):Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2
... a non-profit organization focused on supporting innovative early ... at its fall Fellowship Award Committee review. ... outstanding postdoctoral scientists conducting basic and translational cancer ... across the country. The Fellowship encourages the nation,s ...
... Mozes HealthDay Reporter , WEDNESDAY, Jan. 5 (HealthDay ... amounts of vigorous physical exercise appear to lower their risk ... hours a week or more of vigorous biking, tennis, jogging ... the research team found. But they added that even moderate ...
... 5 (HealthDay News) -- The number of American adults treated for ... 9 million to 19 million, says a federal government report released ... diabetes increased from 4.3 million to 8 million among people age ... 45 to 64; and 1.2 million to 2.4 million among people ...
... Gehrig,s disease, or amyotrophic lateral sclerosis (ALS), and frontotemporal ... brain and spinal-cord cells that include an RNA-binding protein ... of the lesions formed by these clumps. ... Clinical Investigation , a team led by Virginia M.-Y. ...
... HealthDay Reporter , WEDNESDAY, Jan. 5 (HealthDay News) ... be treatable with a vaccine that has been engineered ... with a cocaine-like substance that mimics cocaine,s molecular composition. ... effective and long-lasting antibody immune response, attacking cocaine molecules ...
... at Mount Sinai School of Medicine has developed the ... This instrument has recently been used by soldiers returning ... in the Sixth Annual Road to Recovery Conference and ... TBI. "Traumatic brain injury is underdiagnosed, and ...
Cached Medicine News:Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 3Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 4Health News:Exercise May Improve Odds Against Prostate Cancer Death 2Health News:Exercise May Improve Odds Against Prostate Cancer Death 3Health News:Exercise May Improve Odds Against Prostate Cancer Death 4Health News:Diabetes Soaring Among American Adults: Report 2Health News:Malfunctioning gene associated with Lou Gehrig's disease leads to nerve-cell death in mice 2Health News:Vaccine Protects Mice From Cocaine's Effects, Study Finds 2Health News:Vaccine Protects Mice From Cocaine's Effects, Study Finds 3Health News:Mount Sinai develops first screening tool for war veterans to assess traumatic brain injury 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: